The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Differential predictive impact of PD-L1 expression on immunotherapy outcomes and immunophenotype in squamous versus non-squamous NSCLC.
 
Valentina Santo
No Relationships to Disclose
 
Arielle Elkrief
Honoraria - Astrazeneca; Bristol-Myers Squibb; EMD Serono; Merck
Consulting or Advisory Role - Bristol Myers Squibb
Research Funding - AstraZeneca (Inst); Kanvas Bioscience (Inst); Merck (Inst)
Other Relationship - Canadian Institutes of Health Research (CIHR); Cedars Cancer Center; Royal College of Surgeons and Physicians of Canada
 
Kyle Concannon
No Relationships to Disclose
 
Alessandro Di Federico
Honoraria - Society for Immunotherapy of Cancer
Consulting or Advisory Role - Hanson Wade; Novartis
 
Malini Gandhi
No Relationships to Disclose
 
Federica Pecci
No Relationships to Disclose
 
Edoardo Garbo
No Relationships to Disclose
 
Eleonora Gariazzo
No Relationships to Disclose
 
Francesco Paoloni
No Relationships to Disclose
 
Mihaela Aldea
Consulting or Advisory Role - Viatris
Research Funding - Amgen (Inst); AstraZeneca (Inst)
Travel, Accommodations, Expenses - Sandoz
 
Lynette Sholl
Stock and Other Ownership Interests - Moderna Therapeutics (I)
Consulting or Advisory Role - AstraZeneca; Genentech (Inst); Lilly (Inst)
Research Funding - Bristol Myers Squibb (Inst); Roche/Genentech (Inst)
 
Scott Rodig
Leadership - Immunitas
Stock and Other Ownership Interests - Immunitas
Honoraria - Bristol-Myers Squibb; Perkin Elmer
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Affimed Therapeutics; Bristol-Myers Squibb; Kite, a Gilead Company; Merck
Patents, Royalties, Other Intellectual Property - Patent pending for use of Anti-galectin1 antibodies for diagnostic use.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Adam Schoenfeld
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Enara Bio; Heat Biologics; Immunocore; Iovance Biotherapeutics; Johnson & Johnson/Janssen; KSQ Therapeutics; Legend Biotech; Lyell Immunopharma; Merck; Oppenheimer; Perceptive Advisors; Prelude Therapeutics; Umoja Biopharma
Research Funding - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Harpoon therapeutics; Instil Bio; Iovance Biotherapeutics; Merck; PACT Pharma
Travel, Accommodations, Expenses - Instil Bio; Iovance Biotherapeutics
Other Relationship - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Harpoon therapeutics; Instil Bio; Iovance Biotherapeutics; Merck; PACT Pharma
 
Natalie Vokes
Honoraria - Cardinal Health; Guardant Health; HMP; Medlive; OMNI Health Media; OncLive/MJH Life Sciences; PlatformQ Health; Sanofi; Targeted Oncology
Consulting or Advisory Role - Amgen; AstraZeneca; EMD Serono; ImmunityBio; Lilly; OncoCyte; Oncohost; Pfizer; Regeneron; Remedy Health; Sanofi; Sanofi/Regeneron; Summit pharmaceuticals; Tempus; Xencor
Research Funding - Amgen; Bristol Myers Squibb; Circulo; EMD Serono/Merck; IDEAYA Biosciences; Mirati Therapeutics; OncoCyte; Summit Health
Travel, Accommodations, Expenses - Regeneron
 
Biagio Ricciuti
Honoraria - Targeted Oncology
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Guidepoint Inc; Regeneron